2015
Blunted suppression of acyl‐ghrelin in response to fructose ingestion in obese adolescents: The role of insulin resistance
Van Name M, Giannini C, Santoro N, Jastreboff AM, Kubat J, Li F, Kursawe R, Savoye M, Duran E, Dziura J, Sinha R, Sherwin RS, Cline G, Caprio S. Blunted suppression of acyl‐ghrelin in response to fructose ingestion in obese adolescents: The role of insulin resistance. Obesity 2015, 23: 653-661. PMID: 25645909, PMCID: PMC4548801, DOI: 10.1002/oby.21019.Peer-Reviewed Original ResearchConceptsAcyl ghrelinObese insulinGlucose ingestionInsulin resistanceObese adolescentsCross-over designFructose ingestionGut hormonesChildhood obesityInsulin sensitivityFructose consumptionEffect of glucoseDiminished suppressionRandom orderIngestionObesityPYYAdolescentsInsulinSuppression differencesGlucoseMinutesResponseGhrelinOIR
2012
Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents
Sakharova OV, Lleva RR, Dziura JD, Spollett GR, Howell SK, Beisswenger PJ, Inzucchi SE. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents. Journal Of Diabetes And Its Complications 2012, 26: 333-338. PMID: 22541894, DOI: 10.1016/j.jdiacomp.2012.03.027.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedBlood GlucoseBody WeightCross-Over StudiesDiabetes Mellitus, Type 2FastingFemaleGlycated HemoglobinGlycation End Products, AdvancedHumansHypoglycemic AgentsInsulin GlargineInsulin LisproInsulin, Long-ActingMaleMiddle AgedPostprandial PeriodTreatment FailureTreatment OutcomeConceptsOral anti-hyperglycemic drugsPost-prandial glucoseInsulin strategiesFree fatty acidsType 2Post-prandial glucose metabolismProgressive β-cell dysfunctionType 2 diabetes patientsPost-prandial glucose levelsDaily insulin glargineInitial insulin regimenPrecursor of AGEsSingle-center studyClinical Research CenterLong-term diabetic complicationsAnti-hyperglycemic drugsType 2 diabetesΒ-cell dysfunctionCross-over designInitial insulinInsulin regimenOral agentsInsulin regimensInsulin therapyOAD therapy